generations of glp 1 agonists Science Behind GIP and Glucagon Receptor for Obesity Research | News & Announcements Timeline of GLP-1 discovery and

124 GLP-1, by activating its receptor, increases insulin secretion and reduces glucagon secretion, thereby lowering blood sugar levels

[DOI] [Google Scholar] 22.Crabtree T., Adamson K., Bickerton A., Evans A., Phillips S., Gallagher A., Larsen N., Barnes D., Dhatariya K., Field B.C., et al

While this study was not a head-to-head clinical trial comparison, it may be relevant that at week 12 of a weekly dosing regimen, some studies suggest that participants treated with semaglutide (Wegovy, Novo Nordisk) had an approximately 6% decrease from baseline in body weight, whereas those treated with tirzepatide (Zepbound, Eli Lilly) had an approximately 8% decrease from baseline in body weight at the same time period, Bays said

The researchers analysis found a significant association between GLP-1 use and reduced breast cancer risk

In addition, rising public awareness about weight management and cardiometabolic health is fueling further demand